161 related articles for article (PubMed ID: 32720857)
1. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression.
Zhou YL; Liu WJ; Wang CY; Zheng W; Lan XF; Weng SY; Ning YP
J Psychopharmacol; 2021 Feb; 35(2):159-167. PubMed ID: 32720857
[TBL] [Abstract][Full Text] [Related]
2. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.
Riva-Posse P; Reiff CM; Edwards JA; Job GP; Galendez GC; Garlow SJ; Saah TC; Dunlop BW; McDonald WM
J Affect Disord; 2018 Aug; 236():291-297. PubMed ID: 29525051
[TBL] [Abstract][Full Text] [Related]
4. Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh DA; Niciu MJ; Ionescu DF; Nolan NM; Richards EM; Brutsche NE; Guevara S; Zarate CA
J Affect Disord; 2014 Apr; 159():56-61. PubMed ID: 24679390
[TBL] [Abstract][Full Text] [Related]
5. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
6. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
Wang JCC; Swainson J
J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
[No Abstract] [Full Text] [Related]
7. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence.
Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Cha DS; Nasri F; Gill H; Lui LMW; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
Expert Opin Drug Saf; 2020 Aug; 19(8):1031-1040. PubMed ID: 32539491
[TBL] [Abstract][Full Text] [Related]
9. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation.
Zhan Y; Zhang B; Zhou Y; Zheng W; Liu W; Wang C; Li H; Chen L; Yu L; Walter M; Li M; Li MD; Ning Y
J Affect Disord; 2019 May; 251():205-212. PubMed ID: 30927581
[TBL] [Abstract][Full Text] [Related]
10. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Lan XF; Zhang B; Ning YP
J Affect Disord; 2020 Oct; 275():38-43. PubMed ID: 32658821
[TBL] [Abstract][Full Text] [Related]
11. Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis.
Wang M; Zhang B; Zhou Y; Wang C; Zheng W; Liu W; Zhan Y; Lan X; Ning Y
Pharmacol Rep; 2021 Apr; 73(2):594-603. PubMed ID: 33387333
[TBL] [Abstract][Full Text] [Related]
12. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
[TBL] [Abstract][Full Text] [Related]
13. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
Lenze EJ; Farber NB; Kharasch E; Schweiger J; Yingling M; Olney J; Newcomer JW
World J Biol Psychiatry; 2016 Apr; 17(3):230-8. PubMed ID: 26919405
[TBL] [Abstract][Full Text] [Related]
14. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
Niciu MJ; Shovestul BJ; Jaso BA; Farmer C; Luckenbaugh DA; Brutsche NE; Park LT; Ballard ED; Zarate CA
J Affect Disord; 2018 May; 232():310-315. PubMed ID: 29501990
[TBL] [Abstract][Full Text] [Related]
15. Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Psychopharmacol; 2019 Apr; 33(4):494-501. PubMed ID: 30789302
[TBL] [Abstract][Full Text] [Related]
16. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
Włodarczyk A; Cubała WJ
Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32050466
[TBL] [Abstract][Full Text] [Related]
17. Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up.
Kwon JH; Sim WS; Hong JP; Song IS; Lee JY
J Clin Pharm Ther; 2018 Aug; 43(4):581-583. PubMed ID: 29372569
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.
Ludwig VM; Sauer C; Young AH; Rucker J; Bauer M; Findeis H; Ritter P
CNS Drugs; 2021 Aug; 35(8):881-892. PubMed ID: 34283390
[TBL] [Abstract][Full Text] [Related]
19. Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression.
Del Sant LC; Sarin LM; Magalhães EJM; Lucchese AC; Tuena MA; Nakahira C; Fava VAR; Delfino R; Surjan J; Steiglich MS; Barbosa M; Abdo G; Cohrs FM; Liberatori A; Del Porto JA; Lacerda ALT; de Jesus Mari J
J Psychopharmacol; 2020 Oct; 34(10):1155-1162. PubMed ID: 32638662
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
